The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: A systematic review

Health Technology Assessment

Volumn 10, Issue 24, 2006, Pages

  Connock, M ^a   Burls, A ^a   Frew, E ^a   Fry Smith, A ^a   Juarez Garcia, A ^a   McCabe, C ^b   Wailoo, A ^b   Abrams, K ^c   Cooper, N ^c   Sutton, A ^c   O'Hagan, A ^b   Moore, D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; CALCIUM; CHITOTRIOSIDASE; DNA; GLUCOSYLCERAMIDASE; HEMOGLOBIN; IMIGLUCERASE; IMMUNOGLOBULIN G; MIGLUSTAT; ZAVESKA;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADOLESCENT; ADULT; AGE; ANALYTICAL ERROR; ANAPHYLACTIC SHOCK; ANEMIA; AVASCULAR NECROSIS; BIBLIOGRAPHIC DATABASE; BLEEDING; BONE DENSITY; BONE DISEASE; BONE MARROW; BONE MARROW BIOPSY; BONE PAIN; CHILD; CINAHL; CLINICAL FEATURE; CLINICAL OBSERVATION; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DELAYED PUBERTY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DNA DETERMINATION; DRUG COST; DRUG EFFICACY; DRUG LEGISLATION; DRUG WITHDRAWAL; EMBASE; ENZYME ANALYSIS; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FACTUAL DATABASE; FATIGUE; FEMALE; GAUCHER DISEASE; GENOTYPE PHENOTYPE CORRELATION; GROWTH RETARDATION; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH STATUS; HEPATOMEGALY; HUMAN; HYPOCALCEMIA; IMMOBILIZATION; INDIVIDUALIZATION; INFECTION; LIVER WEIGHT; LUNG DISEASE; MALE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; META ANALYSIS; MORBIDITY; NATIONAL HEALTH SERVICE; NAUSEA; NOCICEPTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PRECOCIOUS PUBERTY; PREDICTION; PREGNANCY; PROBABILITY; PRURITUS; PULMONARY HYPERTENSION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; SAMPLE SIZE; SCISEARCH; SCORING SYSTEM; SENSITIVITY ANALYSIS; SEROCONVERSION; SHORT FORM 36; SPLENECTOMY; SPLENOMEGALY; SURVIVAL RATE; SYMPTOM; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED KINGDOM; URTICARIA; WELLBEING; ECONOMICS; ENZYMOLOGY;

COST-BENEFIT ANALYSIS; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GREAT BRITAIN; HUMANS; STATE MEDICINE; TREATMENT OUTCOME;

EID: 33745696605     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta10240     Document Type: Review

References (166)

1. Futerman AH, Van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 2004;5:554-65.
2. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004;27:385-410.
3. Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A. New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 2004; 25:147-51.
4. Radin NS. Chemotherapy by slowing glucosphingolipid synthesis. Biochem Pharmacol 1999;57:589-95.
5. Cox TM, Schofield JP. Gaucher's disease: clinical features and natural history. Baillière's Clin Haematol 1997;10:657-89.
6. Beutler E. Gaucher disease. Curr Opin Hematol 1997;4:19-23.
7. Erikson A. Gaucher disease - Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand 1986;(suppl 326):1-42.
8. Beutler E, Grabowski GA. Gaucher disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, et al., editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 2001. pp. 3635-68.
9. Cremin BJ, Davey H, Goldblatt J. Skeletal complications of type I Gauchcr disease: the magnetic resonance features. Clin Radiol 1990; 41:244-7.
10. Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine 1985;64:310-22.
11. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox T, Giralt M, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;4(4):4-14.
12. Genzyme Corporation website. http://www.lysosomallearning.com/healthcare/ about/lsd_hc_abt_gaucher2.asp. Accessed 24 February 2005.
13. Chabas A, Gort L, Montfort M, Castello F, Dominguez MC, Grinberg D, et al. Recurrence of the D409H mutation in Spanish Gaucher disease patients: description of a new homozygous patient and haplotype analysis. J Med Genet 1998; 35:775-7.
14. Brady RO, Barton NW, Grabowski GA. The role of neurogenetics in Gaucher disease. Arch Neurol 1993;50:1212-24.
15. Patterson MC, Horowitz M, Abel RB, Currie JN, Yu KT, Kaneski C, et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease. Neurology 1993;43:1993-7.
16. Zimran A, Gross E, West C, Sorge J, Kubitz M, Beutler E. Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet 1989;334:349-52.
17. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine 1992;71:337-53.
18. Stone DL, Tayebi N, Orvisky E, Stubblefield B, Madike V, Sidransky E. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat 2000;15:181-8.
19. Walley AJ, Barth ML, Ellis I, Fensom AH, Harris A. Gaudier's disease in the United Kingdom: screening non-Jewish patients for the two common mutations. J Med Genet 1993;30:280-3.
20. Hatton CE, Cooper A, Whitehouse C, Wraith JE. Mutation analysis in 46 British and Irish patients with Gaucher's disease. Arch Dis Child 1997; 77:17-22.
21. Mistry PK, Abrahamov A. A practical approach to diagnosis and management of Gaucher's disease. Baillière's Clinical Haematology 1997; 10:817-38.
22. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-92.
23. Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 1999;12:167-76.
24. Holcomb GW III, Greene HL. Fatal hemorrhage caused by disease progression after partial splenectomy for type III Gaucher's disease. J Pediatr Surg 1993;28:1572-4.
25. Kyllerman M, Conradi N, Mansson JE, Percy AK, Svennerholm L. Rapidly progressive type III Gaucher disease: deterioration following partial splenectomy. Acta Paediatr Scand 1990;79:448-53.
26. Brady RO. Enzyme replacement therapy: conception, chaos and culmination. Philos Trans R Soc Lond B Biol Sci 2003;358:915-19.
27. Genzyme product leaflet. 2005. URL: http://www.genzyme.co.uk/thera/cz/ uk_pdf_cz_pi.pdf Accessed February 2005.
28. Schiffmann R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, et al. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 2002;28:288-96.
29. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5.
30. Zimran A, Elstein D. Gaucher disease and the clinical experience with substrate reduction therapy. Philos Trans R Soc Lond B Biol Sci 2003; 358:961-6.
31. Moyses C. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci 2003;358:955-60.
32. Gaucher's disease guidelines - adult type 1. Report No. 1. London: Lysosomal storage disorders Unit, Royal Free Hampstead NHS Trust; 2003.
33. Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JTR, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004; 4(4):15-22.
34. Baldellou A, Andria G, Campbell PE, Charrow J, Cohen IJ, Grabowski GA, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67-75.
35. West Midlands Interim Commissioning Policy for the Capitation-based Risk Sharing Arrangement. 2004. West Midlands Specialist Services Agency, Edgbaston, Birmingham.
36. URL: http:/europa.eu.int/eur-lex/pri/en/oj/dat/2000/1_018/ 1_01820000122en00010005.pdf. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of December 16, 1999 on Orphan Medicinal Products. Official Journal of the European Communities 2000;1-5.
37. British National Formulary. 48th ed. London: Royal Pharmaceutical Society of Great Britain 2004.
38. West Midlands Health Technology Assessment Collaboration. Clinical and cost-effectiveness of enzyme replacement therapy for Gaucher's disease. A rapid review. University of Birmingham; 2004.
39. Morales LE. Gaucher's disease: a review. Ann Pharmacother 1996;30:381-8.
40. Undertaking systematic reviews of research on effectiveness; CRD's guidance for those carrying out or commissioning reviews. Report No. 4. 2nd ed. York: York Publishing Services; 2001.
41. Hallam L, Bryant J. Ceredase in the treatment of type 1 Gaucher's disease. Southampton: Wessex Institute for Health Research and Development; 1996.
42. Czartoryska B, Tylki-Szymanska A, Gorska D, Sawnor-Korszynska D. Lipidoses detected in Poland through 1993. Pediatr Neurol 1994; 11:295-7.
43. Krasnopolskaya KD, Mirenburg TV, Aronovich EL, Lebedeva TV, Odinokova ON, Demina NA, et al. Diagnosis and prevention of lysosomal storage diseases in Russia. J Inherit Metab Dis 1993; 16:994-1002.
44. Coelho J, Wajner M, Burin MG, Vargas CR, Giugliani R. Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism. Eur J Pediatr 1997;156:650-4.
45. Michelakakis H, Dimitriou E, Tsagaraki S, Giouroukos S, Schulpis K, Bartsocas CS. Lysosomal storage diseases in Greece. Genet Couns 1995;6:43-7.
46. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-6.
47. Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 2004; 12:87-92.
48. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
49. Dionisi-Vici C, Rizzo C, Burlina AB, Caruso U, Sabetta G, Uziel G, et al. Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. J Pediatr 2002; 140:321-7.
50. Ozhara AH, Topcu M. Sphingolipidoses in Turkey. Brain Dev 2004;26:363-6.
51. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000;105:art-e10.
52. Goldblatt J, Beighton P. Gaucher disease in the Afrikaner population of South Africa. S Afr Med J 1979;55:209-10.
53. Swart AL, Hesseling PB, Hayden MR, Louw M, Herbert JS. Gaucher's disease in the Cape coloured population of the RSA, including a family with 5 affected siblings. S Afr Med J 1987; 71:97-9.
54. Fried K. Population study of chronic Gaucher's disease. Israel Journal of Medical Sciences 1973; 9:1396-8.
55. Giraldo P, Pocovi M, Perez-Calvo J, Rubio-Felix D, Giralt M. Report of the Spanish Gaucher's Disease Registry: clinical and genetic characteristics. Haematologica 2000;85:792-9.
56. National statistics; UK at a glance. 2005. URL: http://www.statistics.gov.uk/. Accessed 3 April 2005.
57. The world fact book; Netherlands. 2005. URL: http://www.cia.gov/cia/ publications/factbook/geos/nl.html. Accessed 4 April 2005.
58. Poll LW, vom Dahl S, Koch JA, Borner D, Willers R, Cohnen M, et al. Gaucher disease: MR evaluation of bone marrow features during treatment with enzyme replacement. RoFo Fortschr Geb Rontgenstr Bildgeb Verfahr 2001;173:931-7.
59. Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, et al. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol 2001; 30:496-503.
60. Trial for new enzyme replacement therapy for Gaucher disease to take place in Israel. 2004. URL: http://www.gaucher.org.uk/oct04tkttrial.htm. Accessed September 2004.
61. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, et al. Enzyme therapy in type 1 Gaucher disease. comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-9.
62. Rice EO, Mifflin TE, Sakallah S, Lee RE, Sansieri CA, Barranger JA. Gaucher disease: studies of phenotype, molecular diagnosis and treatment. Clin Genet 1996;49:111-8.
63. Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol Dis 2004;32:214-17.
64. Vlieger EJ, Maas M, Akkerman EM, Hollak CE, Den Heeten GJ. Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease. J Comput Assist Tomogr 2002; 26:843-8.
65. Dayan B, Elstein D, Zimran A, Nesher G. Decreased salivary output in patients with Gaucher disease. QJM 2003;96:53-6.
66. Cohen Y, Elstein D, Abrahamov A, Hirsch H, Zimran A. HCG contamination of alglucerase: clinical implications in low-dose regimen. Am J Hematol 1994;47:235-6.
67. Richards SM, Olson TA, McPherson JM. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 1993;82:1402-9.
68. Olsen E, McHugh K, Vellodi A. Routine magnetic resonance imaging of the spine in children with Gaucher disease: does it help therapeutic management? Pediatr Radiol 2003;33:782-5.
69. Kaplan P, Mazur A, Manor O, Charrow J, Esplin J, Gribble TJ, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996;129:149-53.
70. Alfonso P, Cenarro A, Perez-Calvo JI, Puzo J, Giralt M, Giraldo P, et al. Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease. Med Clin (Barc) 2003; 120:641-6.
71. Beutler E, Demina A, Laubscher K, Garver P, Gelbart T, Balicki D, et al. The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol Dis 1995;21:86-108.
72. Dweck A, Abrahamov A, Hadas-Halpern I, Bdolach-Avram T, Zimran A, Elstein D. Type I Gaucher disease in children with and without enzyme therapy. Pediatr Hematol Oncol 2002; 19:389-97.
73. Elstein D, Hadas-Halpern I, Itzchaki M, Lahad A, Abrahamov A, Zimran A. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis 1996;22:104-11.
74. Elstein Y, Eisenberg V, Granovsky-Grisaru S, Rabinowitz R, Samueloff A, Zimran A, et al. Pregnancies in Gaucher disease: a 5-year study. Am J Obst Gynecol 2004;190:435-41.
75. Hollak C, Maas M, Akkerman E, den Heeten A, Aerts H. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 2001; 27:1005-12.
76. Ida H, Rennert OM, Kato S, Ueda T, Oishi K, Maekawa K, et al. Severe skeletal complications in Japanese patients with type 1 Gaucher disease. J Inherit Metab Dis 1999;22:63-73.
77. Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2000;2:158-63.
78. 99mTc-sestamibi. J Nucl Med 2003;44:1253-62.
79. Mistry PK, Sirrs S, Chan A, Pritzker MR, Thomas PD, Grace ME, et al. Pulmonary hypertension in type I Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002;77:91-8.
80. Murray GJ, Howard KD, Richards SM, Barton NW, Brady RO. Gaucher's disease: lack of antibody response in 12 patients following repeated intravenous infusions of mannose terminal glucocerebrosidase. J Immunol Methods 1991; 137:113-20.
81. Terk MR, Dardashti S, Liebman HA. Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. Skeletal Radiol 2000;29:563-71.
82. Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, et al. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease [comment]. Blood Cells Mol Dis 2000;26:285-90.
83. Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 2001; 138:539-47.
84. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-70.
85. Beck M, Mengel E, Barone R. Enzyme replacement therapy: a new treatment concept in Gaucher disease. Wien Klin Wochenschr 1997; 109:81-5.
86. Belmatoug N, de Villemeur TB. Skeletal response to enzyme replacement therapy foe type 1 Gaucher disease: a preliminary report of the French experience. Semin Hematol 1995; 32(3 Suppl 1):33-8.
87. Bembi B, Zanatta M, Carrozzi M, Baralle F, Gornati R, Berra B, et al. Enzyme replacement treatment in type 1 and type 3 Gaucher's disease. Lancet 1994;344:1679-82.
88. Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ. Bone complications in children with Gaucher disease. Br J Radiol 2002; 75:A37-43.
89. Caubel I, de Villemeur TB, Belmatoug N, Comité d'Étude du Traitement de la Maladie de Gaucher. Gaucher's disease in children: first clinical signs, natural course and benefits of enzyme replacement therapy. Arch Pediatr 2003;10:681-8.
90. Cohen IJ, Katz K, Kornreich L, Horev G, Frish A, Zaizov R. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol Dis 1998;24:296-302.
91. Damiano AM, Pastores GM, Ware JE Jr. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 1998;7:373-86.
92. Ehlen C, Heintges T, Niederau C. Diagnosis and therapy of Gaucher disease. Med Klin 1995; 90:284-90.
93. Elstein D, Abrahamov A, Hadas-Halpern I, Meyer A, Zimran A. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM 1998;91:483-8.
94. Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Withdrawal of enzyme replacement therapy in Gaucher's disease. Br J Haematol 2000; 110:488-92.
95. Fallet S, Grace ME, Sibille A, Mendelson DS, Shapiro RS, Hermann G, et al. Enzyme augmentation in moderate to life-threatening Gaucher disease. Pediatr Res 1992;31:496-502.
96. Figueroa ML, Rosenbloom BE, Kay AC, Garver P, Thurston DW, Koziol JA, et al. A less costly regimen of alglucerase to treat Gaucher's disease. N Engl J Med 1992;327:1632-6.
97. Giraldo P, Rubio-Felix D, Perez-Calvo J, Giralt M. Quality of life in patients with Gaucher's disease type 1: influence of enzyme replacement therapy. Third Conference of the International Society for Quality of Life Studies, Universitat de Girona, 2000; pp. 199-201.
98. Hayes RP, Grinzaid KA, Duffey EB, Elsas LJ. The impact of Gaucher disease and its treatment on quality of life. Qual Life Res 1998;7:521-34.
99. Hollak CE, Corssmit EP, Aerts JM, Endert E, Sauerwein HP, Romijn JA, et al. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease. Am J Med 1997;103:185-91.
100. Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, et al. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 1995;345:1474-8.
101. Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 1997; 96:470-6.
102. Ida H, Rennert OM, Kobayashi M, Eto Y. Effects of enzyme replacement therapy in thirteen Japanese paediatric patients with Gaucher disease. Eur J Pediatr 2001;160:21-5.
103. Lorberboym M, Pastores GM, Kim CK, Hermann G, Glajchen N, Machac J. Scintigraphic monitoring of reticuloendothelial system in patients with type 1 Gaucher disease on enzyme replacement therapy. J Nucl Med 1997;38:890-5.
104. MacKenzie JJ, Amato D, Clarke JT. Enzyme replacement therapy for Gaucher's disease: the early Canadian experience. CMAJ 1998; 159:1273-8.
105. Magnaldi S, Longo R, Ukmar M, Zanatta M, Bottega M, Sottocasa GL. Bone marrow relaxation times in Gaucher disease before and after enzyme replacement therapy. Eur Radiol 1997;7:486-91.
106. Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK. Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 1999;8:263-8.
107. Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993;82:408-16.
108. Patlas M, Hadas-Halpern I, Abrahamov A, Elstein D, Zimran A. Spectrum of abdominal sonographic findings in 103 pediatric patients with Gaucher disease. Eur Radiol 2002;12:397-400.
109. Patlas M, Hadas-Halpern I, Abrahamov A, Zimran A, Elstein D. Repeat abdominal ultrasound evaluation of 100 patients with type I Gaucher disease treated with enzyme replacement therapy for up to 7 years. Hematol J 2002;3:17-20.
110. Perez-Calvo JI, Giraldo P, Giralt M. Spanish Group on Gaucher's Disease. Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Sangre 1997;42:189-94.
111. Poll LW, Koch JA, Willers R, Aerts H, Scherer A, Haussinger D, et al. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol Dis 2002; 28:209-20.
112. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999;93:2081-8.
113. Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995;96:629-37.
114. Schaison G, Caubel I, Belmatoug N, de Villemeur TB, Saudubray JM. French results of enzyme replacement therapy in Gaucher's disease. Bull Acad Natl Med 2002;186:851-61.
115. Verderese CL, Graham OC, Holder-McShane CA, Harnett NE, Barton NW. Gaucher's disease: a pilot study of the symptomatic responses to enzyme replacement therapy. J Neurosci Nurs 1993; 25:296-301.
116. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-19.
117. Zaizov R, Frisch A, Cohen IJ. Lower-dose, high-frequency enzyme replacement therapy in children with type 1 Gaucher disease: experience at the Schneider Children's Medical Center of Israel. Semin Hematol 1995;32(3 Suppl 1):39-44.
118. Zimran A, Hollak CE, Abrahamov A, van Oers MH, Kelly M, Bender E. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood 1993;82:1107-9.
119. Zimran A, Hadas-Halpern I, Zevin S, Levy-Lahad E, Abrahamov A. Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease. Br J Haematol 1993; 85:783-6.
120. Zimran A, Elstein D, Kannai R, Zevin S, Hadas-Halpern I, Levy-Lahad E, et al. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment [comment]. Am J Med 1994;97:3-13.
121. Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpern I, Bar-Ziv Y, et al. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995;345:1479-80.
122. Erikson A, Astrom M, Mansson JE. Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease. Neuropediatrics 1995;26:203-7.
123. Charrow J, Andersson HC, Kaplan P, Kolodny E, Mistry P, Pastores G, et al. Response to enzyme replacement therapy in Gaucher disease patients with N370S/N370S, N370S compound heterozygotes and L444P/L444P genotypes. Am J Hum Genet 2000;67:2411.
124. Drugan C, Procopciuc L, Jebeleanu G, Grigorescu-Sido P, Dussau J, Poenaru L, et al. Gaucher disease in Romanian patients: incidence of the most common mutations and phenotypic manifestations. Eur J Hum Genet 2002;10:511-15.
125. Maaswinkel-Mooij P, Hollak C, Eysden-Plaisier M, Prins M, Aerts H, Poll R. The natural course of Gaucher disease in the Netherlands: implications for monitoring of disease manifestatiotis. J Inherit Metab Dis 2000;23:77-82.
126. Ida H, Rennert OM, Ito T, Maekawa K, Eto Y. Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. Blood Cells Mol Dis 1998;24:73-81.
127. Boot RG, Hollak CE, Verhoek M, Sloof P, Poorthuis BJ, Kleijer WJ, et al. Glucocerebrosidase genotype of Gaucher patients in the Netherlands: limitations in prognostic value. Hum Mutat 1997; 10:348-58.
128. Woodfield MJ, Woodfield DG, Winship IM. Clinical and molecular aspects of Gaucher disease in New Zealand. N Z Med J 1997;110:316-19.
129. Sibille A, Eng CM, Kim SJ, Pastores G, Grabowski GA. Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications. Am J Hum Genet 1993;52:1094-101.
130. Amaral O, Lacerda L, Santos R, Pinto RA, Aerts H, Sa Miranda MC. Type 1 Gaucher disease: molecular, biochemical, and clinical characterization of patients from northern Portugal. Biochemical Medicine and Metabolic Biology 1993;49:97-107.
131. Hodson P, Goldblatt J, Beighton P. Non-neuropathic Gaucher disease presenting in infancy. Arch Dis Child 1979;54:707-9.
132. Goldblatt J, Beighton P. Gaucher's disease in South Africa. J Med Genet 1979;16:302-5.
133. Matoth Y, Zaizov R, Hoffman J, Klibansky C. Clinical and biochemical aspects of chronic Gaucher's disease. Israel Journal of Medical Sciences 1974;10:1523-9.
134. Beighton P, Sacks S. Gaucher's disease in southern Africa. S Afr Med J 1974;48:1295-9.
135. Lee RE. The pathology of gaucher disease. Gaucher disease: a century of delineation and research. New York: Alan R. Liss; 1982. pp. 117-217.
136. Gielchinsky Y, Elstein D, Hadas-Halpern I, Lahad A, Abrahamov A, Zimran A. Is there a correlation between degree of splenomegaly, symptoms and hypersplenism? A study of 218 patients with Gaucher disease. Br J Haematol 1999;106:812-16.
137. Santamaria F, Parenti G, Guidi G, Filocamo M, Strisciuglio P, Grillo G, et al. Pulmonary manifestations of Gaucher disease: an increased risk for L444P homozygotes? Am J Respir Crit Care Med 1998;157:985-9.
138. Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in type 1 Gaucher disease. J Bone Miner Res 1996;11:1801-7.
139. Kerem E, Elstein D, Abrahamov A, Bar ZY, Hadas-Halpern I, Melzer E, et al. Pulmonary function abnormalities in type I Gaucher disease. Eur Respir J 1996;9:340-5.
140. Terk MR, Esplin J, Lee K, Magre G, Colletti PM. MR imaging of patients with type 1 Gaucher's disease: relationship between bone and visceral changes. AJK Am J Roentgenol 1995;165:599-604.
141. Katz K, Sabato S, Horev G, Cohen IJ, Yosipovitch Z. Spinal involvement in children and adolescents with Gaucher disease. Spine 1993;18:332-5.
142. Cohen IJ, Katz K, Freud E, Zer M, Zaizov R. Long-term follow-up of partial splenectomy in Gaucher's disease. Am J Surg 1992;164:345-7.
143. Fleshner PR, Aufses AH, Jr, Grabowski GA, Elias R. A 27-year experience with splenectomy for Gaucher's disease. Am J Surg 1991;161:69-75.
144. Zlotogora J, Sagi M, Zeigler M, Bach G. Gaucher disease type I and pregnancy. Am J Med Genet 1989;32:475-7.
145. Ashkenazi A, Zaizov R, Matoth Y. Effect of splenectomy on destructive bone changes in children with chronic (type I) Gaucher disease. Eur J Pediatr 1986;145:138-41.
146. Goldblatt J, Sacks S, Beighton P. The orthopedic aspects of Gaucher disease. Clin Orthop 1978; 137:208-14.
147. Ciana G, Martini C, Leopaldi A, Tamaro G, Katouzian F, Ronfani L, et al. Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 2003;72:185-9.
148. Hermann G, Goldblatt J, Levy RN, Goldsmith SJ, Desnick RJ, Grabowski GA. Gaucher's disease type 1: assessment of bone involvement by CT and scintigraphy. Am J Roentgenol 1986;147:943-8.
149. NIH Technology Assessment Panel on Gaucher Disease. Gaucher disease. Current issues in diagnosis and treatment. JAMA 1996;275:548-53.
150. Ida H, Rennert OM, Kato S, Ueda T, Oishi K, Maekawa K, et al. Severe skeletal complications in Japanese patients with type 1 Gaucher disease. J Inherit Metab Dis 1999;22:63-73.
151. Harats D, Pauzner R, Elstein D, Many A, Klutstein MW, Kramer MR, et al. Pulmonary hypertension in two patients with type I Gaucher disease while on alglucerase therapy. Acta Haematol 1997;98:47-50.
152. Ida H, Rennert OM, Kawame H, Maekawa K, Eto Y. Mutation prevalence among 47 unrelated Japanese patients with Gaucher disease: identification of four novel mutations. J Inherit Metab Dis 1997;20:67-73.
153. Clarke AE, Goldstein MK, Michelson D, Garber AM, Lenert LA. The effect of assessment method and respondent population on utilities elicited for Gaucher disease. Qual Life Res 1997; 6:169-84.
154. Pastores GM. Quality of life assessments: to measure the health-related burden of Gaucher disease and treatment outcome. Clinical Perspectives on Lysosomal Storage Disorders 2002;10(2):16-9.
155. Giraldo P, Solano V, Perez-Calvo J, Giralt M, Rubio-Felix D, Spanish Group on Gaucher's Disease. Quality of life related to type 1 Gaucher's disease: Spanish experience. Qual Life Res 2005; 14:453-61.
156. Beutler E, Garber AM. Alglucerase for Gaucher's disease: dose, costs and benefits. Pharmacoeconomics 1994;5:453-9.
157. Whittington R, Goa KL. Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease. Pharmacoeconomics 1995;7:63-90.
158. Beutler E, Kay A, Saven A, Garver P, Thurston D, Dawson A, et al. Enzyme replacement therapy for Gaucher disease. Blood 1991;78:1183-9.
159. Beutler E. The cost of treating Gaucher disease. Nat Med 1996;2:523-4.
160. Clarke JT, Amato D, Deber RB. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario. CMAJ 2001;165:595-6.
161. Discussion Paper 172. UK population norms for EQ-5D. York: University of York Centre for Health Economics; 1999.
162. Curtis L, Netten A. Unit costs of health and social care. 12th ed. Canterbury: PSSRU, University of Kent; 2004.
163. Stevenson M, Lloyd-Jones M, De Nigris E, Brewer N, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9(22).
164. Bluis J. Genzyme feels the heat. 2005. URL: http://www.fool.com/news/mft/2005/mft05012636htm?source= eptyholnk303100&logvisit=y&npu=y&bounce=y&bounce2=y. Accessed 10 March 2005.
165. Brazier J. The SF-36 Health Survey Questionnaire - a tool for economists. Health Econ 1993;2:213-15.
166. NHS reference costs 2003. http://www.dh.gov.uk/PublicationsAndStatistics/ Publications/PublicationsPolicyAndGuidance/ PublicationsPolicyAndGuidanceArticle/fs/ en?CONTENT_ID=4070195&chk=UzhHA3. Accessed January 2005.